Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 10Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Hemangiosarcoma 1HER2-positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Trastuzumab 18Radiosurgery 15Capecitabine 13Lapatinib 11Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 7Temozolomide 6tucatinib 4pembrolizumab 4paclitaxel-Angiopep-2 conjugate 4eribulin 4Vinorelbine 4Specimen Handling 4Paclitaxel 4Methotrexate 4Cisplatin 4sacituzumab govitecan 3pyrotinib 3abemaciclib 3Radiation 3Fluorodeoxyglucose F18 3pertuzumab 2palbociclib 2neratinib 2durvalumab 2cediranib 2cabazitaxel 2Sodium Chloride 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × ARX788 × Breast × Clear all
NCT05018702 2022-06-01

ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

Fudan University

Phase 2 Unknown
32 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡